Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Short interest for healthcare stocks in S&P 500 rose slightly in December vs. November, while Moderna continued to be the most shorted stock of the month. The average short interest for S&P 500 Health ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

The Nasdaq-100 Index® is composed of 100 of the largest non-financial c CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the ...